Carson Advisory’s Lipocine LPCN Stock Holding History

Carson Advisory’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,059	Closed	-$16.5K	–	161
2023 Q1	$16.5K	Buy	+3,059	New	+$23.6K	0.01%	150
2022 Q3	–	Sell	-3,059	Closed	-$42K	–	130
2022 Q2	$42K	Buy	+3,059	New	+$47.7K	0.05%	122

Other funds holding LPCN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Carson Advisory's LPCN Position: Q2 2023 in Review

Carson Advisory sold out of Lipocine (LPCN) in Q2 2023, closing a stake of 3,059 shares — an estimated $16.5K sold.

Carson Advisory first reported a position in LPCN in Q2 2022 and held it in 2 quarters. The position peaked at $42K in Q2 2022. 24 funds tracked by Wall St. Rank hold LPCN as of Q2 2023.

Carson Advisory reported no remaining Lipocine position as of Q2 2023 after selling out during the quarter.
Carson Advisory sold 3,059 Lipocine shares in Q2 2023, an estimated $16.5K.
Carson Advisory first reported a position in Lipocine in Q2 2022 and held it in 2 quarters.
Carson Advisory's Lipocine position peaked at $42K in Q2 2022.
24 funds tracked by Wall St. Rank held Lipocine as of Q2 2023.

Based on Carson Advisory's 13F filing for Q2 2023, filed 27 Jul 2023.